JAK2 and prostate cancer: Consistent with our observations of sensitivity to JAK2 inhibition, analysis of phospho-proteomics data from three previously-characterized pairs of enzalutamide-resistant lines (Ware et al., 2020), including CS2 enzalutamide-sensitive and -resistant lines demonstrates increased phosphorylation of STAT1, STAT2, JAK1, and JAK2 (Figures 6E–H), pinpointing the JAK/STAT signaling axis as a potential therapeutic vulnerability for Snail+ and enzalutamide-resistant prostate cancer.